NHS Tier 3 vs private weight loss — an honest cost and access comparison

The two routes, briefly

The NHS pathway for adult weight management is tiered. Tier 1 is community/lifestyle support, Tier 2 is structured behaviour change programmes, Tier 3 is specialist multi-disciplinary weight management services (MDT-based, often including dietitians, psychology, exercise specialists, and prescribers), and Tier 4 is bariatric surgery. NICE TA1026 (tirzepatide) and TA875 (semaglutide) place GLP-1 prescribing within specialist services — effectively Tier 3.

The private route is direct: a consultation with a prescriber, an MHRA-licensed prescription within a structured weight management programme, and ongoing support. The licence criteria are broader than the NHS NICE thresholds, the waiting time is days rather than months, and you pay for the programme.

Eligibility — where the routes differ

NICE for NHS access: BMI ≥35 (≥32.5 in some ethnic groups, including South Asian, Chinese, Black African, and African-Caribbean) plus at least one weight-related comorbidity, delivered through specialist services. Treatment is currently capped at two years.

MHRA for private prescribing: BMI ≥30, or 27–30 with at least one weight-related comorbidity. No formal two-year cap; clinical decisions are made by the prescriber within the structured programme.

If your BMI is between 27 and 35 with comorbidity, the NHS route may not be open to you, but private prescribing within the MHRA licence is. If your BMI is ≥35 with comorbidity, both routes are technically open — it then comes down to waiting time, what's included, and cost.

What each pathway includes

NHS specialist weight management (when accessible):

• Multi-disciplinary assessment — often dietitian, psychology input, exercise specialist alongside the prescriber.
• Structured group or 1:1 behavioural support over months.
• Prescription within a programme of ongoing review.
• Two-year treatment cap.
• No out-of-pocket prescription charges beyond the standard NHS prescription charge (or free in Scotland, Wales, Northern Ireland).

Private structured programme (responsible providers):

• Clinical consultation with a prescriber (often a GP, pharmacist independent prescriber, or specialist).
• Dietary and behavioural support, often more frequent than NHS but usually less multi-disciplinary.
• Monitoring through dose escalation and at maintenance.
• Side effect support and clinical contact.
• No formal time cap, but continuation is clinically reviewed.
• Out-of-pocket cost for the medication and the programme.

What private prescribing generally does not include: dedicated psychology input, supervised exercise specialist sessions, or surgical referral pathways. If your weight management needs those components, the NHS specialist route is the better fit even if the wait is longer.

Waiting times — the practical question

NHS waiting times for specialist weight management vary enormously by ICB — from a few months to well over a year in some areas. Your GP can usually confirm what your local pathway looks like. The wait isn't a reflection of clinical urgency; it's a function of capacity.

Private prescribing is usually available within days to a couple of weeks, including the consultation. That's the main thing people are buying when they go private — access timing as much as the medication itself.

Cost — what 'cost' actually means

The NHS pathway has no medication cost beyond standard prescription charges (free in much of the UK). What it does have, for some patients, is the indirect cost of unpaid leave for appointments, travel, and waiting time.

Private prescribing carries an out-of-pocket cost for the medication, the consultation, and the programme. We don't list prices in this guide because they vary by dose and by what's included. The principle that matters: a pen-only price is not a programme price. Compare what's included — consultations, monitoring, dietary support, clinician access for side effects — not just the pen.

A useful exercise: ask any private service exactly what's included in the headline price. If the answer doesn't cover consultation, monitoring, and clinician access for side effects, the headline price is misleading and the real total is higher.

Moving between the routes

Many patients start privately while waiting for an NHS referral, then transition when a slot opens. The other direction is also possible.

A few practical notes:

• Tell both teams. Don't get the same medication prescribed twice or have an NHS clinician unaware of your private dose history.
• Bring records. The receiving team needs your current dose, recent weight, side effect history, and any blood test results.
• The two-year NHS treatment cap matters. If you've had close to two years of NHS treatment, your continuing options after that may be private. Plan ahead.

A framework for choosing

Think about it in this order:

1. Are you NHS eligible? If BMI ≥35 (≥32.5 some ethnic groups) with comorbidity, ask your GP about referral. The MDT input alone is worth the wait for many people.
2. Is the wait workable? If your local pathway is short, NHS is the obvious answer. If it's 12+ months and you have meaningful comorbidities now, private might bridge it.
3. What support do you actually need? If you need psychology, supervised exercise, or surgical pathway access, NHS specialist services are designed for that. Private prescribing isn't.
4. What does the total private cost include? Compare programmes, not pens. A complete programme costs more than a pen — because it includes the things that make the medication work safely.
5. Can you transition later? Yes — but plan it. Don't end up with two parallel prescriptions or a gap during a dose increase.

What we tell patients in clinic

If you're eligible for NHS Tier 3 and the wait in your area is reasonable, the NHS pathway is usually the right starting point. If the wait is long, you have meaningful comorbidities, and you can comfortably afford a structured private programme, private is a reasonable bridge. If you don't meet NHS criteria but you do meet the MHRA licence (BMI 27–30 with comorbidity), private prescribing is the route that's open to you, and a well-structured pharmacist-led programme is a sensible model.

We don't push patients toward private when NHS fits. That's not great medicine and it's not great long-term business either.

The next step

If you want to talk through which route suits you — NHS, private, or a planned combination — a 20–30 minute consultation is the easiest way to get clear answers. Bring your last BMI, any comorbidity diagnoses, what your GP has said about referral, and any concerns about cost or wait time. The aim of the conversation is the right route for you, not necessarily ours.